Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CaboAveNEC Trial
NCT05289856Phase 2Completed
- Sponsor
- Johannes Gutenberg University Mainz
- Start
- Mar 2022
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in Neuroendocrine neoplasm (NEN), sponsored by Johannes Gutenberg University Mainz. Started Mar 2022; status: completed.
02
Drugs
cabozantinib
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT05289856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289856.